A new type of treatment which lowers blood fat has been trialled in patients with heart disease and in patients with hardening of the arteries in the legs. A TICR researcher, Prof Jill Belch has, with others, have written the European Guideline https://t.
2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia. https://t.co/9D5kxwms4Q
RT @RevistaMFSamfyc: Actualización 2017 del grupo de trabajo sobre guías de práctica clínica de ESC/EAS de la inhibición de PCSK9 en pacie…
Actualización 2017 del grupo de trabajo sobre guías de práctica clínica de ESC/EAS de la inhibición de PCSK9 en pacientes con enfermedad cardiovascular aterosclerótica o en hipercolesterolemia familiar https://t.co/oaSc6NqKto PMID 29045644
RT @krychtiukmd: 2017 ESC/EAS update on the use of PCSK9 Inhibitors in this issue of @ESC_journals @escardio #Cardiology #Lipids #lipidol…
RT @krychtiukmd: 2017 ESC/EAS update on the use of PCSK9 Inhibitors in this issue of @ESC_journals @escardio #Cardiology #Lipids #lipidol…
RT @krychtiukmd: 2017 ESC/EAS update on the use of PCSK9 Inhibitors in this issue of @ESC_journals @escardio #Cardiology #Lipids #lipidol…
RT @krychtiukmd: 2017 ESC/EAS update on the use of PCSK9 Inhibitors in this issue of @ESC_journals @escardio #Cardiology #Lipids #lipidol…
RT @krychtiukmd: 2017 ESC/EAS update on the use of PCSK9 Inhibitors in this issue of @ESC_journals @escardio #Cardiology #Lipids #lipidol…
RT @krychtiukmd: 2017 ESC/EAS update on the use of PCSK9 Inhibitors in this issue of @ESC_journals @escardio #Cardiology #Lipids #lipidol…
RT @krychtiukmd: 2017 ESC/EAS update on the use of PCSK9 Inhibitors in this issue of @ESC_journals @escardio #Cardiology #Lipids #lipidol…
RT @krychtiukmd: 2017 ESC/EAS update on the use of PCSK9 Inhibitors in this issue of @ESC_journals @escardio #Cardiology #Lipids #lipidol…
2017 ESC/EAS update on the use of PCSK9 Inhibitors in this issue of @ESC_journals @escardio #Cardiology #Lipids #lipidology @TheFHFoundation #Atherosclerosis @EASCongress @SilCastelletti @rafavidalperez https://t.co/E7JWZj9f4O
2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin typ... https://t.co/Ou822a6NgI
2017 Update of ESC/EAS Task Force on practical clinical guidance for PCSK9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia #ESC #EHJ https://t.co/wZUKGQXUQf
2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia https://t.co/GKGt5V7WTD
RT @krychtiukmd: Must Read! Clinical Guidance Paper by ESC and EAS on PCSK9-i use in clinical practice @escardio @EASCongress #ESCCoT #ACCF…
RT @jvillacastin: Documento de la Soc. Europea de Cardio sobre cuándo utilizar inhibidores de PCSK9 en pacientes con enfermedad ateroscleró…
RT @krychtiukmd: Must Read! Clinical Guidance Paper by ESC and EAS on PCSK9-i use in clinical practice @escardio @EASCongress #ESCCoT #ACCF…
RT @krychtiukmd: Must Read! Clinical Guidance Paper by ESC and EAS on PCSK9-i use in clinical practice @escardio @EASCongress #ESCCoT #ACCF…
RT @krychtiukmd: Must Read! Clinical Guidance Paper by ESC and EAS on PCSK9-i use in clinical practice @escardio @EASCongress #ESCCoT #ACCF…
RT @krychtiukmd: Must Read! Clinical Guidance Paper by ESC and EAS on PCSK9-i use in clinical practice @escardio @EASCongress #ESCCoT #ACCF…
Must Read! Clinical Guidance Paper by ESC and EAS on PCSK9-i use in clinical practice @escardio @EASCongress #ESCCoT #ACCFIT #Cardiology #CardioEd #Cardiotwitter #Lipids #PCSK9 https://t.co/yfboVrGhsF https://t.co/AVKAi6cWAM
RT @jvillacastin: Documento de la Soc. Europea de Cardio sobre cuándo utilizar inhibidores de PCSK9 en pacientes con enfermedad ateroscleró…
RT @jvillacastin: Documento de la Soc. Europea de Cardio sobre cuándo utilizar inhibidores de PCSK9 en pacientes con enfermedad ateroscleró…
RT @jvillacastin: Documento de la Soc. Europea de Cardio sobre cuándo utilizar inhibidores de PCSK9 en pacientes con enfermedad ateroscleró…
RT @jvillacastin: Documento de la Soc. Europea de Cardio sobre cuándo utilizar inhibidores de PCSK9 en pacientes con enfermedad ateroscleró…
RT @jvillacastin: Documento de la Soc. Europea de Cardio sobre cuándo utilizar inhibidores de PCSK9 en pacientes con enfermedad ateroscleró…
RT @jvillacastin: Documento de la Soc. Europea de Cardio sobre cuándo utilizar inhibidores de PCSK9 en pacientes con enfermedad ateroscleró…
RT @jvillacastin: Documento de la Soc. Europea de Cardio sobre cuándo utilizar inhibidores de PCSK9 en pacientes con enfermedad ateroscleró…
RT @jvillacastin: Documento de la Soc. Europea de Cardio sobre cuándo utilizar inhibidores de PCSK9 en pacientes con enfermedad ateroscleró…
Documento de la Soc. Europea de Cardio sobre cuándo utilizar inhibidores de PCSK9 en pacientes con enfermedad aterosclerótica cardiovascular. https://t.co/HB8d4wSixk https://t.co/dtrD4lKKJT
2017 Update of ESC/EAS Task Force on PCG for PCSK9 inhibition in patients with ACVD or in FH https://t.co/UNQD57RarX https://t.co/jJl6BpNt6L
RT @qgorgas: 2017 Update of ESC/EAS practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition https://t.co/c…
2017 Update of ESC/EAS practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition https://t.co/cLIFYzui31
RT @rincondesisifo: (Eur Heart J) Actualización de la GPC de uso de iPCSK9 en pac con aterosclerosis CV o hipercolesterolemia familiar htt…
(Eur Heart J) Actualización de la GPC de uso de iPCSK9 en pac con aterosclerosis CV o hipercolesterolemia familiar https://t.co/nZfmHwgz8J
Of note: lower LDL thresholds for considering PCSK9 inhibitors for FH pts in updated ESC guidance @TheFHFoundation https://t.co/V6j34dMDB0
Update of the ESC recommendations on PCSK9 inhibitors - Hope this will be useful @TheFHFoundation @escardio https://t.co/oe14qbSx6R
RT @ArsenaultBenoit: New ESC/EAS update on PCSK9 inhibition guidelines in patients with ASCVD or familial hypercholesterolaemia https://t.c…
RT @ArsenaultBenoit: New ESC/EAS update on PCSK9 inhibition guidelines in patients with ASCVD or familial hypercholesterolaemia https://t.c…
RT @ArsenaultBenoit: New ESC/EAS update on PCSK9 inhibition guidelines in patients with ASCVD or familial hypercholesterolaemia https://t.c…
New ESC/EAS update on PCSK9 inhibition guidelines in patients with ASCVD or familial hypercholesterolaemia https://t.co/8Evb94Ef2w #KnowFH https://t.co/qafrwUkCQV
RT @Office_j: 【雑記】ESCとEASは、アテローム性心血管疾患を有するFH例への、PCSK9抗体ガイダンスを更新。 EHJ https://t.co/WfABuFfNlW (オープンアクセスではありません)
【雑記】ESCとEASは、アテローム性心血管疾患を有するFH例への、PCSK9抗体ガイダンスを更新。 EHJ https://t.co/WfABuFfNlW (オープンアクセスではありません)
2017 Update of ESC/EAS Task Force on practical clinical guidance for PCSK9 inhibition https://t.co/0ATEqTR2es https://t.co/AhWicScd3K